Gabapentin Capsule
Product Images NDC 68071-3527

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68071-3527). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3527 9)

Gabapentin 300 mg capsules packaging label from NuCare Pharmaceuticals, Inc. It shows a quantity of 90 capsules. The label describes the capsule as oblong with '300mg' printed in grey on the white body and 'OE B57' on the yellow cap. It includes the product number P1212090, NDC 68071-3527-9, and storage instructions to keep at controlled temperature 68-77°F and out of reach of children.*

FDA Label Image

Chemical Structure (Gabapenin 01)

Chemical structure diagram showing the molecular arrangement of gabapentin, highlighting its cyclohexane core with attached amino and carboxyl functional groups.*

FDA Label Image

Figure 1 (Gabapenin 02)

A line graph displaying mean pain scores over an 8-week period comparing placebo and gabapentin 3,600 mg/day. The timeline includes a 4-week dose titration period followed by a 4-week fixed dose period, with pain scores generally decreasing more in the gabapentin group versus placebo.*

FDA Label Image

Figure 2 (Gabapenin 03)

A line graph depicting mean pain scores over a 7-week period comparing placebo and Gabapentin at doses of 1,800 mg/day and 2,400 mg/day. The x-axis indicates time in weeks, with a 3-week dose titration period followed by a 4-week fixed dose period, while the y-axis shows mean pain scores from 0 to 10.*

FDA Label Image

Figure 3 (Gabapenin 04)

A bar chart comparing two studies showing the percentage outcomes of placebo (PBO) versus Gabapentin (GBP) at different doses. Study 1 compares placebo with GBP 3,600 mg, and Study 2 compares placebo with GBP 1,800 mg and 2,400 mg doses. Statistical significance indicators are noted with p-values less than 0.01 and 0.001, highlighting differences between groups.*

FDA Label Image

Figure 4 (Gabapenin 05)

A scatter plot comparing percentage differences across three studies (a, b, and c) at various daily doses of gabapentin (600, 900, 1200, and 1800 mg). The y-axis represents difference (%) and the x-axis shows daily dose in mg. Study data points are marked with different shaded squares.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.